UCBBelgian biopharma UCB has agreed to acquire clinical-stage biotech Neurona Therapeutics for up to US$1.15 billion, betting on a one-off cell therapy that aims to structurally repair the brains of people with drug-resistant epilepsy.
Tag Archive for: Acquisition
Tubulis GmbHFor Tubulis, the time for an exit has arrived: US based pharma group Gilead is set to pay up to US$5bn for the biotech’s ADC expertise.
Novartis GroupNovartis is back on the acquisition trail, agreeing to buy California-based Excellergy for up to $2bn. The antibody Exl-111 is intended to strengthen its allergy pipeline and go beyond the current standard of care. The deal is part of a broader string of acquisitions aimed at systematically expanding the group’s innovation base.
adobe stock photos - Michael Derrer Fuchs Novartis is pressing ahead with its aggressive expansion strategy in oncology, striking again: the Basel-based group is acquiring a novel PI3Kalpha inhibitor from Synnovation Therapeutics for up to USD 3 billion.
Unsplash+French pharma giant Servier is spending US$2.5bn to snap up Day One Biopharmaceuticals, gaining a key approved drug for difficult childhood brain tumours along with several promising pipeline candidates.
GSK will pay $950m for Montreal-based 35Pharma to secure HS235, an investigational activin signalling inhibitor that has completed Phase I trials in healthy volunteers and is set to begin studies in pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).
Unsplash+Axol Bioscience has acquired Newcells Biotech’s ophthalmology business to expand its portfolio of drug discovery and safety testing models.
The Westin St. Francis lobby buzzed with its familiar January energy, a peculiar blend of jet lag, ambition, and the faint desperation of biotech CEOs clutching coffee cups like lifelines. This year’s JP Morgan Healthcare Conference arrived with a question hanging in the San Francisco fog: after years of what one executive called “nuclear winter,” were the capital markets finally thawing?
GSK has agreed to acquire California-based RAPT Therapeutics in a deal valued at $2.2 billion (€ 1.88 billion), expanding its respiratory, immunology and inflammation portfolio with a late-stage food allergy candidate. The transaction gives GSK global rights to ozureprubart, a long-acting anti-IgE monoclonal antibody now in phase IIb clinical development.
While much of the biotech industry is focused on meetings and dealmaking at the J.P. Morgan (JPM) Healthcare Conference, a rumor has cut through the JPM noise. The possibility of Eli Lilly making a move on Abivax is back on the table, with a price tag that would imply a valuation close to twice the French company’s current market capitalisation at €8.4 billion ($9.8 billion).